Venous thromboembolic risk and its prevention in hospitalized medical patients

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 6, 2002, Pages 577-583

  Haas, Sylvia K ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Low molecular weight heparins; Medical patients; Pulmonary embolism; Thromboprophylaxis; Venous thrombosis

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; PRACTICE GUIDELINE; PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

CLINICAL TRIALS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 0036915235     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36702     Document Type: Article

References (49)

1. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991;151:933-938
2. Prandoni P, Villalta S, Bagatelle P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-428
3. Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000;60:575-595
4. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-205
5. Mandelli V, Schmid C, Zogno C, Morpurgo M. "False negatives" and "false positives" in acute pulmonary embolism: A clinical-postmortem comparison. Cardiologia 1997;42:205-210
6. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(Suppl 1):132S-175S
7. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalized medical patients. J Clin Pathol 1997;50:609-610
8. Goldhaber SZ, Savage DD, Garrison RI, et al. Risk factors for pulmonary embolism - The Framingham study. JAMA 1983;74:1023-1028
9. Anderson FA, Wheeler HB, Goldberg R, et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991;115:591-595
10. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37
11. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-574
12. Second Thromboembolic Risk Factors (THRiFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1999;13:87-97
13. Gensini GF, Prisco D, Falciani M, et al. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost 1997;23:55-67
14. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sirius study. Arch Intern Med 2000;160:3415-3420
15. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-450
16. Belch JJ, Lowe GDO, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-117
17. Anderson GM, Hull E. The effect of dicoumarol upon the mortality and incidence of thromboembolic complication of congestive heart failure. Am Heart J 1950;39:697-702
18. Hirsh DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995;274:335-337
19. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173-182
20. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215-V224
21. Gladman DD, Urowitz M. Venous syndromes and pulmonary embolism in systemic lupus erythematosus. Ann Rheum Dis 1980;39:340-343
22. Talbot RW, Heppel J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-145
23. Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. Cancer 1984; 54:1264-1268
24. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-407
25. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294
26. Pritchard KI, Paterson AHG, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14:2731-2737
27. Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: Results from a prospective, randomized trial. Crit Care Med 1995;23:52-59
28. Bertina RM, Koeleman BP, Köster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
29. Laffen M, Tuddenham E. Assessing thrombotic risk. BMJ 1998;317:520-523
30. Storti S, Crucitti P, Cina G. Risk factors and prevention of venous thromboembolism. RAYS 1996;21:439-460
31. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet 1999;353:1167-1173
32. Haas S. Prophylaxis thromboembolique: Quand? Et pour combien de temps? Tribune Medicale 1998;16:4-5
33. Chapuis Y, Augereau B, Clergue F, et al. Prophylaxie des thromboses veineuses postopératoires: Recommandations de l'Assistance publique-Hôpitaux de Paris. Sang Thromb Vaiss 1995;7:119-120
34. Gardlund B, for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996;347:1357-1361
35. Bergmann J-F, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996;384:205-206 (Letter)
36. Lederle FA. Heparin prophylaxis for medical patients? Ann Intern Med 1998;128:768-770 (Editorial)
37. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982;96:561-565
38. Francis CW, Ricotta JJ, Evarts CM, et al. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip and knee arthroplasty. Clin Orthop 1988;232:271-278
39. Gallus AS, Hirsh J, Tuttle RJ. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973;288:545-550
40. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986;16:159-164
41. Mottier D, for the Geriatric Enoxaparin Study Group. Prophylaxis of deep venous thrombosis in medical geriatric patients. Thromb Haemost 1993;69(Suppl):1115 (Abst)
42. Lechler E, Schramm W, Flosbach CW. The PRIME study group. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 1996;26(Suppl 2):49-56
43. Bergmann J-F, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-534
44. Harenberg J, Roebruck P, Heene DL, for the Heparin Study in Internal Medicine Group. Subcutaneous low-molecular heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996;26:127-139
45. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161:1109-1114
46. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19
47. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800
48. Kleber FX, Witt C, Flosbach CW, et al and the PRINCE Study Group. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease. Thromb Haemost 1999;(Suppl):1552 (Abst)
49. Kleber FX, Flosbach CW, Koppenhagen K, et al. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with hearth failure NYHA III/IV (PRINCE II study). Circulation 1999;100(Suppl I):I-619 (Abst 3265)